Comparing results of neoadjuvant chemotherapy versus adjuvant in high risk bladder cancer patients, NCI, Egypt / by Hagar Shahin Ismail ALzawawy ; under supervision of Dr. Marwa Nabil Abdelhafez, Dr. Ibrahim Abdelaziz Malash.

By:

Hagar Shahin Ismail ALzawawy [preparation.]

Contributor(s):

Material type: Text

TextLanguage: English Summary language: English, Arabic Producer: 2022Description: 70 pages : illustrations ; 25 cm. + CDContent type:

text

Media type:

Unmediated

Carrier type:

volume

Other title:

دراسة استرجاعية للمقارنة بين فوائد العلاج الكيميائى ما قبل العملية و العلاج المساعد فى سرطان المثانة عالية المخاطر للمرضى المترددين بالمعهد القومى للاورام مصر [Added title page title]

Subject(s):

DDC classification:

616.99462 21

Available additional physical forms:

Issues also as CD.

Dissertation note: Thesis (M.Sc.)-Cairo University, 2022. Summary: Bladder cancer is one of the most prevalent cancers globally. Men have a 34-fold higher rate of cancer than women. The gold standard treatment for muscle-invasive bladder cancer is a radical cystectomy (RC). Objective: The present study aimed to assess effectiveness of neoadjuvant chemotherapy on size of tumor; assess the treatment outcome (overall survival and progression free survival) of all cases of urinary bladder cancer. Patients and Methods: The present study aimed to assess effectiveness of neoadjuvant chemotherapy on size of tumor; assess the treatment outcome (overall survival and progression free survival) of all cases of urinary bladder cancer. Most patients presented in an advanced stage of the disease (stages 3 and 4: 60.8% and 17.7%, respectively); (69.6%) of patients had a history of Schistosomiasis. Results: Patients who received neoadjuvant chemotherapy had higher 2-year OS than patients who received adjuvant chemotherapy (56% vs. 48.4%). Patients who received neoadjuvant chemotherapy had higher median OS than patients who received adjuvant chemotherapy (25.1 vs. 22.0 months). Females exhibited a considerably greater 2-year cumulative relapse rate than males (P = 0.010). Patients aged > 50 years having a greater 2-year cumulative incidence of recurrence than patients aged 50 year (P = 0.179). Squamous and Transitional cell histologies (vs. Papillary) connected with a greater risk of recurrence (P = 0.23 and 0.17). Conclusion: Patients who received neoadjuvant chemotherapy had higher OS than patients who received adjuvant chemotherapy. Females exhibited a considerably greater cumulative relapse rate than males. There was statistically significant correlation between gender and recurrence risk.Summary: يعد سرطان المثانة أحد أكثر أنواع السرطان انتشارًا على مستوى العالم. الرجال لديهم 34 ضعفا نسبة الإصابة بالسرطان أعلى من النساء. العلاج القياسي الذهبي للمثانة الغازية للعضلات السرطان هو استئصال المثانة الجذري (RC). الهدف: تهدف الدراسة الحالية إلى تقييم فعالية العلاج الكيميائي المساعد الجديد على حجم الورم تقييم نتائج العلاج (البقاء على قيد الحياة بشكل عام والبقاء على قيد الحياة بدون تقدم). جميع حالات سرطان المثانة البولية. المرضى والطرق: تهدف الدراسة الحالية إلى تقييم فعالية المواد المساعدة الجديدة العلاج الكيميائي على حجم الورم. تقييم نتائج العلاج (البقاء الشامل والتقدم البقاء على قيد الحياة مجانا) لجميع حالات سرطان المثانة البولية. معظم المرضى قدموا في حالة متقدمة

Tags from this library: No tags from this library for this title. Log in to add tags.

Average rating: 0.0 (0 votes)

Holdings
Item type	Current library	Home library	Call number	Status	Date due	Barcode
Thesis	قاعة الرسائل الجامعية - الدور الاول	المكتبة المركزبة الجديدة - جامعة القاهرة	Cai01.19.04.M.Sc.2022.Ha.C (Browse shelf(Opens below))	Not for loan		01010110087732000

Browsing المكتبة المركزبة الجديدة - جامعة القاهرة shelves Close shelf browser (Hides shelf browser)

Previous	No cover image available	No cover image available	No cover image available	No cover image available	No cover image available	No cover image available	No cover image available	Next
Previous	Cai01.19.04.m.sc.2022.Ba.E Evaluation of Intraoperative Pectoral Nerve Block by Surgeon during Modified Radical Mastectomy /	Cai01.19.04.M.Sc.2022.De.T A Ten-Year Retrospective Study Exploring the Outcome Of Triple Negative Breast Cancer In Young Patients In Comparison To Older Patients from 2010- 2019 /	Cai01.19.04.M.Sc.2022.Fa.C C -Kit negative Gastrointestinal Stromal Tumor, Challenges Of Management And Prognosis /	Cai01.19.04.M.Sc.2022.Ha.C Comparing results of neoadjuvant chemotherapy versus adjuvant in high risk bladder cancer patients, NCI, Egypt /	Cai01.19.04.M.Sc.2022.Ib.C Clinicopathological Study and Management of Primary Malignant Scapular Tumors 10 years National Cancer Institute experience /	Cai01.19.04.M.Sc.2022.Ma.F Five year survival analysis of surgically resected gastric cancer cases /	Cai01.19.04.M.Sc.2022.Mo.C Clinico-pathological CHARacteristics and treatment outcomes of patients with stage ii colon cancer, single institutional experience /	Next

Thesis (M.Sc.)-Cairo University, 2022.

Bibliography: pages 34-45.

Bladder cancer is one of the most prevalent cancers globally. Men have a 34-fold
higher rate of cancer than women. The gold standard treatment for muscle-invasive bladder
cancer is a radical cystectomy (RC).
Objective: The present study aimed to assess effectiveness of neoadjuvant chemotherapy on
size of tumor; assess the treatment outcome (overall survival and progression free survival) of
all cases of urinary bladder cancer.
Patients and Methods: The present study aimed to assess effectiveness of neoadjuvant
chemotherapy on size of tumor; assess the treatment outcome (overall survival and progression
free survival) of all cases of urinary bladder cancer. Most patients presented in an advanced
stage of the disease (stages 3 and 4: 60.8% and 17.7%, respectively); (69.6%) of patients had a
history of Schistosomiasis.
Results: Patients who received neoadjuvant chemotherapy had higher 2-year OS than patients
who received adjuvant chemotherapy (56% vs. 48.4%). Patients who received neoadjuvant
chemotherapy had higher median OS than patients who received adjuvant chemotherapy (25.1
vs. 22.0 months). Females exhibited a considerably greater 2-year cumulative relapse rate than
males (P = 0.010). Patients aged > 50 years having a greater 2-year cumulative incidence of
recurrence than patients aged 50 year (P = 0.179). Squamous and Transitional cell histologies
(vs. Papillary) connected with a greater risk of recurrence (P = 0.23 and 0.17).
Conclusion: Patients who received neoadjuvant chemotherapy had higher OS than patients
who received adjuvant chemotherapy. Females exhibited a considerably greater cumulative
relapse rate than males. There was statistically significant correlation between gender and
recurrence risk.

يعد سرطان المثانة أحد أكثر أنواع السرطان انتشارًا على مستوى العالم. الرجال لديهم 34 ضعفا
نسبة الإصابة بالسرطان أعلى من النساء. العلاج القياسي الذهبي للمثانة الغازية للعضلات
السرطان هو استئصال المثانة الجذري (RC).
الهدف: تهدف الدراسة الحالية إلى تقييم فعالية العلاج الكيميائي المساعد الجديد على
حجم الورم تقييم نتائج العلاج (البقاء على قيد الحياة بشكل عام والبقاء على قيد الحياة بدون تقدم).
جميع حالات سرطان المثانة البولية.
المرضى والطرق: تهدف الدراسة الحالية إلى تقييم فعالية المواد المساعدة الجديدة
العلاج الكيميائي على حجم الورم. تقييم نتائج العلاج (البقاء الشامل والتقدم
البقاء على قيد الحياة مجانا) لجميع حالات سرطان المثانة البولية. معظم المرضى قدموا في حالة متقدمة

Issues also as CD.

Text in English and abstract in Arabic & English.

There are no comments on this title.

to post a comment.